Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Vasoconstrictor Agents | 10 | 2018 | 714 | 4.14 | Why? |
| Hypotension | 4 | 2017 | 392 | 2.09 | Why? |
| Shock, Traumatic | 2 | 2017 | 18 | 1.41 | Why? |
| Hemorrhagic Fever, Ebola | 5 | 2019 | 1475 | 1.41 | Why? |
| Ebolavirus | 3 | 2019 | 834 | 0.93 | Why? |
| Fluid Therapy | 4 | 2018 | 628 | 0.85 | Why? |
| Resuscitation | 4 | 2017 | 638 | 0.80 | Why? |
| Spinal Puncture | 1 | 2018 | 95 | 0.70 | Why? |
| Needles | 1 | 2018 | 87 | 0.70 | Why? |
| Blood Pressure | 6 | 2018 | 2198 | 0.68 | Why? |
| Chemoprevention | 2 | 2021 | 585 | 0.66 | Why? |
| Lactoferrin | 1 | 2018 | 208 | 0.63 | Why? |
| Evidence-Based Medicine | 5 | 2020 | 3228 | 0.63 | Why? |
| Shock | 4 | 2020 | 1868 | 0.63 | Why? |
| Shock, Hemorrhagic | 1 | 2017 | 81 | 0.62 | Why? |
| Cerebrovascular Circulation | 1 | 2018 | 340 | 0.57 | Why? |
| Wounds, Nonpenetrating | 1 | 2017 | 157 | 0.56 | Why? |
| Epinephrine | 1 | 2017 | 323 | 0.56 | Why? |
| Disease Management | 5 | 2021 | 6841 | 0.53 | Why? |
| Brain Injuries | 1 | 2017 | 374 | 0.46 | Why? |
| Shock, Septic | 3 | 2018 | 1313 | 0.45 | Why? |
| Randomized Controlled Trials as Topic | 13 | 2021 | 10649 | 0.44 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.43 | Why? |
| Critical Illness | 13 | 2021 | 17281 | 0.41 | Why? |
| Organ Dysfunction Scores | 1 | 2017 | 1475 | 0.41 | Why? |
| Canada | 12 | 2021 | 6018 | 0.38 | Why? |
| Africa, Western | 2 | 2018 | 363 | 0.33 | Why? |
| Critical Care | 6 | 2021 | 14081 | 0.31 | Why? |
| Brain Injuries, Traumatic | 2 | 2019 | 381 | 0.26 | Why? |
| Disease Outbreaks | 4 | 2019 | 27595 | 0.25 | Why? |
| Hydroxychloroquine | 4 | 2021 | 12447 | 0.23 | Why? |
| Intensive Care Units | 14 | 2021 | 29594 | 0.22 | Why? |
| Brain | 1 | 2018 | 5133 | 0.21 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.21 | Why? |
| Patient Transfer | 2 | 2018 | 898 | 0.21 | Why? |
| Adrenal Cortex Hormones | 5 | 2021 | 6537 | 0.21 | Why? |
| Carrageenan | 1 | 2021 | 123 | 0.20 | Why? |
| Tissue Donors | 3 | 2018 | 1679 | 0.20 | Why? |
| Research Design | 4 | 2021 | 5830 | 0.19 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.19 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.19 | Why? |
| Spin Labels | 1 | 2018 | 36 | 0.19 | Why? |
| Humans | 58 | 2021 | 930598 | 0.19 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.18 | Why? |
| Hypertension | 2 | 2018 | 8895 | 0.18 | Why? |
| Catecholamines | 1 | 2018 | 66 | 0.18 | Why? |
| Chlorine | 1 | 2018 | 55 | 0.18 | Why? |
| Post-Dural Puncture Headache | 1 | 2018 | 33 | 0.18 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.18 | Why? |
| Vasopressins | 1 | 2018 | 70 | 0.17 | Why? |
| Early Termination of Clinical Trials | 2 | 2020 | 1256 | 0.17 | Why? |
| Respiration, Artificial | 8 | 2021 | 22116 | 0.17 | Why? |
| Electrolytes | 1 | 2018 | 103 | 0.17 | Why? |
| Therapeutic Equipoise | 1 | 2017 | 52 | 0.17 | Why? |
| Organizational Culture | 1 | 2020 | 395 | 0.17 | Why? |
| Deep Sedation | 1 | 2018 | 121 | 0.16 | Why? |
| Efficiency, Organizational | 1 | 2020 | 482 | 0.16 | Why? |
| Community-Acquired Infections | 2 | 2020 | 2328 | 0.16 | Why? |
| Conflict of Interest | 1 | 2018 | 175 | 0.15 | Why? |
| Albumins | 1 | 2018 | 324 | 0.15 | Why? |
| Sodium Chloride | 1 | 2017 | 203 | 0.15 | Why? |
| Financing, Government | 1 | 2020 | 434 | 0.15 | Why? |
| Arterial Pressure | 1 | 2017 | 208 | 0.15 | Why? |
| Peritoneal Dialysis | 1 | 2021 | 498 | 0.14 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.14 | Why? |
| Models, Organizational | 1 | 2020 | 908 | 0.14 | Why? |
| Adult | 20 | 2021 | 244371 | 0.14 | Why? |
| Graft Survival | 1 | 2017 | 587 | 0.13 | Why? |
| Research Report | 1 | 2018 | 376 | 0.13 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.13 | Why? |
| Oxygen Consumption | 1 | 2018 | 711 | 0.13 | Why? |
| Uncertainty | 2 | 2021 | 1888 | 0.12 | Why? |
| Observational Studies as Topic | 2 | 2017 | 1887 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.12 | Why? |
| Logistic Models | 5 | 2021 | 9089 | 0.12 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.12 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.11 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.11 | Why? |
| World Health Organization | 2 | 2021 | 4213 | 0.11 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.11 | Why? |
| Male | 22 | 2021 | 367725 | 0.11 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.11 | Why? |
| Troponin I | 1 | 2019 | 1298 | 0.10 | Why? |
| Continuity of Patient Care | 2 | 2018 | 1574 | 0.10 | Why? |
| Anti-Infective Agents | 2 | 2021 | 1766 | 0.10 | Why? |
| Hyperglycemia | 1 | 2021 | 1363 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.10 | Why? |
| Interprofessional Relations | 1 | 2017 | 1013 | 0.10 | Why? |
| Africa | 1 | 2019 | 2986 | 0.10 | Why? |
| Heart Injuries | 1 | 2016 | 608 | 0.10 | Why? |
| Informed Consent | 1 | 2016 | 890 | 0.10 | Why? |
| Ritonavir | 2 | 2021 | 4212 | 0.10 | Why? |
| Pilot Projects | 5 | 2019 | 5182 | 0.09 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.09 | Why? |
| Thrombosis | 2 | 2021 | 7504 | 0.09 | Why? |
| Pain Management | 1 | 2017 | 854 | 0.09 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.09 | Why? |
| Female | 20 | 2021 | 380317 | 0.09 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.09 | Why? |
| Feasibility Studies | 4 | 2019 | 3467 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Network Meta-Analysis | 2 | 2020 | 426 | 0.09 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.09 | Why? |
| Aged | 15 | 2021 | 215776 | 0.09 | Why? |
| Aerosols | 2 | 2021 | 5393 | 0.09 | Why? |
| Time Factors | 7 | 2020 | 31397 | 0.08 | Why? |
| Politics | 1 | 2020 | 1824 | 0.08 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.08 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.08 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Prospective Studies | 8 | 2019 | 43301 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Diarrhea | 1 | 2019 | 2743 | 0.08 | Why? |
| Graft Rejection | 1 | 2017 | 1766 | 0.08 | Why? |
| Tissue and Organ Procurement | 1 | 2017 | 1277 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.08 | Why? |
| Wounds and Injuries | 1 | 2019 | 1708 | 0.08 | Why? |
| Drug Combinations | 3 | 2021 | 3852 | 0.08 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.08 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.08 | Why? |
| Organ Transplantation | 2 | 2017 | 2616 | 0.07 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.07 | Why? |
| Electrocardiography | 1 | 2019 | 3957 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Patient Discharge | 1 | 2019 | 5696 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2019 | 3361 | 0.06 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.06 | Why? |
| Decision Making | 1 | 2016 | 3132 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Fever | 1 | 2019 | 7795 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Attitude of Health Personnel | 1 | 2019 | 4741 | 0.05 | Why? |
| Length of Stay | 4 | 2020 | 11042 | 0.05 | Why? |
| Peer Review, Health Care | 1 | 2019 | 8 | 0.05 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Amodiaquine | 1 | 2019 | 57 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2020 | 10083 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Epidemiologic Studies | 1 | 2021 | 554 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.04 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| High-Frequency Ventilation | 1 | 2017 | 57 | 0.04 | Why? |
| Motor Activity | 1 | 2019 | 217 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Artemisinins | 1 | 2019 | 238 | 0.04 | Why? |
| Publication Bias | 1 | 2018 | 241 | 0.04 | Why? |
| Neuromuscular Blocking Agents | 1 | 2017 | 121 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.04 | Why? |
| Guideline Adherence | 2 | 2020 | 2309 | 0.04 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.04 | Why? |
| Review Literature as Topic | 1 | 2019 | 387 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Mental Competency | 1 | 2016 | 128 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Tidal Volume | 1 | 2017 | 565 | 0.04 | Why? |
| Documentation | 1 | 2018 | 332 | 0.03 | Why? |
| Cannula | 1 | 2020 | 750 | 0.03 | Why? |
| Depression | 1 | 2019 | 14116 | 0.03 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.03 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.03 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.03 | Why? |
| Lactic Acid | 1 | 2017 | 393 | 0.03 | Why? |
| Single-Blind Method | 1 | 2018 | 1283 | 0.03 | Why? |
| Blood Gas Analysis | 1 | 2017 | 893 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.03 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Patients' Rooms | 1 | 2018 | 675 | 0.03 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.03 | Why? |
| Professional-Patient Relations | 1 | 2017 | 426 | 0.03 | Why? |
| Oropharynx | 1 | 2021 | 1581 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Vitamins | 1 | 2021 | 1208 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Hospital Units | 1 | 2017 | 1017 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.02 | Why? |
| Positive-Pressure Respiration | 1 | 2017 | 1160 | 0.02 | Why? |
| Switzerland | 1 | 2017 | 2738 | 0.02 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.02 | Why? |
| Lung | 1 | 2017 | 31049 | 0.02 | Why? |
| Retrospective Studies | 2 | 2017 | 105322 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2017 | 1530 | 0.02 | Why? |
| Pyrazines | 1 | 2019 | 1783 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Amides | 1 | 2019 | 1864 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Quality of Health Care | 1 | 2019 | 1948 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Quality Improvement | 1 | 2019 | 2435 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Prone Position | 1 | 2017 | 1861 | 0.02 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.02 | Why? |
| Caregivers | 1 | 2019 | 3112 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Patient Safety | 1 | 2019 | 4885 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.01 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
Lamontagne's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1428)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_